ak 295 has been researched along with Brain Ischemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, A; Baker, KL; Bartus, RT; Dean, RL; Elliott, PJ; Harbeson, SL; Hayward, NJ; Li, Z; Sawyer, SD; Straub, JA | 1 |
| Andersson, AL; Bahr, BA; Blomgren, K; Hagberg, H; Hallin, U; Kawashima, S; McRae, A; Puka-Sundvall, M; Saido, TC | 1 |
2 other study(ies) available for ak 295 and Brain Ischemia
| Article | Year |
|---|---|
Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration.
Topics: Animals; Brain Ischemia; Calpain; Dipeptides; Dose-Response Relationship, Drug; Injections, Intra-Arterial; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley | 1994 |
Calpastatin is up-regulated in response to hypoxia and is a suicide substrate to calpain after neonatal cerebral hypoxia-ischemia.
Topics: Animals; Animals, Newborn; Brain; Brain Ischemia; Calcium-Binding Proteins; Calpain; Cell Membrane; Cysteine Proteinase Inhibitors; Dipeptides; Enzyme Activation; Female; Functional Laterality; Hypoxia; Male; Rats; Rats, Wistar; Up-Regulation | 1999 |